Atrium Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $234.5M
- Price
- $13.71
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.78%
- Volume
- 360.1K
About
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Quick stats
Shares outstanding17.1M
Computed float16.2M
Float / shares95.0%
Cash runway (months)27.3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002093101
AI Summary
AI-generated1/10
majorbullishearnings
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Atrium Therapeutics announced FDA IND clearance for its lead candidate ATR 1072 and initiated the Phase 1/2 Corventis trial for PRKAG2 syndrome.
The company achieved a second milestone under its collaboration with Bristol Myers Squibb, triggering a $15 million payment to be recognized in the third quarter.
Q2 net loss widened to $20.2 million with R&D expenses rising to $15.3 million, while cash and short-term investments of $263.9 million are expected to fund operations into mid-2028.